Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471027 | 0.93 | KMT2A (0.60) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL15324712 | 0.90 | KMT2A (0.47) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL7470585 | 0.83 | USP2 (0.56) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5510675 | 0.82 | KMT2A (0.51) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL7472662 | 0.82 | L3MBTL1 (0.43) | KMT2AMEN1GAAMAPK1L3MBTL1 | |
| SCHEMBL5802317 | 0.82 | L3MBTL1 (0.43) | KMT2AMEN1GAAMAPK1L3MBTL1 | |
| SCHEMBL7463453 | 0.82 | HSD17B10 (0.48) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL7475254 | 0.81 | HSD17B10 (0.46) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL7464304 | 0.81 | L3MBTL1 (0.42) | KMT2AMEN1GAAMAPTMAPK1 | |
| SCHEMBL19023500 | 0.80 | USP2 (0.44) | KMT2AMEN1ALDH1A1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814878-B1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1814878-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2006068770-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| EP-0869949-B1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO MCNEIL PHARM INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-5854242-A | Benzoxazine antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-5696117-A | BACTERICIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167254-A1 | Spiro 2,4-pyrimidinediamine compounds and their uses | SSB, SPHK2, PKD2 | KMT2A 1826/4885MEN1 1498/4885ALDH1A1 1308/4885 |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | KMT2A 1711/4885MEN1 1548/4885ALDH1A1 1187/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | KMT2A 3656/4885MEN1 4809/4885ALDH1A1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.